VIM and prostate cancer: In regard to the marker of the EMT, linear regression, analyses showed a positive and significant correlation between the number of vimentin-positive prostate cancer cells and 18F–choline uptake evaluated in terms of SUV average (r2 = 0.2787; p < 0.0001) (Figure 2B).